StockGuide AI
Suivre des actions
EN RU ES DE IT PT FR
Merck

Merck

Prix: 119.05

Entreprise et modèle économique

Merck & Co., Inc. is a global healthcare company that develops and manufactures pharmaceuticals, vaccines, biologics, and animal health products. Its core products include treatments for cancer, diabetes, and infectious diseases, with significant revenue generated from its oncology and vaccine segments. The company also focuses on research and development to innovate new therapies and improve existing ones.

Profil d’investissement

The stock presents a balanced investment profile, appealing to investors seeking a combination of growth and income through dividends. With a moderate dividend yield and a focus on innovation, it may attract those interested in stable returns while also considering potential capital appreciation.

Site officiel

Métriques fondamentales (expérimental)

BPA (TTM) — bénéfice par action des 12 derniers mois, $
3.56 OK
Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
-0.2% ≈
Surprise BPA
1.5% conforme
Volatilité 20 j
2.1% stable
Rendement du dividende
3.5% modéré dernière date ex-dividende: 2026-06-15
Données FMP / FinFeed mises à jour: 2026-06-09
Reco: Acheter Potentiel: 67 Risque: 40 Mis à jour: 2026-06-13 02:52
Comment fonctionne la recommandation
Pourquoi l’IA pense cela:
Stable dividend, but mixed momentum signals present uncertainty.

Suivre dans le portefeuille

Graphique des prix

Recommandation IA Prévision d’analyste Événement calendrier Signal positif Signal négatif Neutre / mise à jour Conserver / informatif B My buy S My sell
Changements de recommandation IA
Date Avant Après Raison
2026-06-09 02:45 Conserver Acheter Stable dividend, moderate growth, cautious market sentiment.
2026-06-01 02:45 Acheter Conserver Solid dividend yield, but mixed momentum signals.
2026-05-24 02:45 Conserver Acheter Strong momentum and solid dividend yield support growth.
Prévisions des analystes
Date Analyste Action Objectif Prix alors
2026-06-02 10:48 Guggenheim Mettre à jour — → 140 115.21
2026-05-01 16:03 Morgan Stanley Objectif relevé 109 → 112 112.47
2026-03-12 11:05 Wells Fargo Objectif relevé — → 150 116.22
Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

06/09/2026, 12:32 AM growth pharma space Merck Redwire Eli Lilly
The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.